Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

On November 15, 2021, Cerus Corporation (CERS) will participate in the Stifel 2021 Virtual Healthcare Conference, featuring CEO William ‘Obi’ Greenman and CFO Kevin D. Green. The event is set for 4:40 p.m. ET, with a live webcast available on Cerus' Investor Relations page. Cerus is focused on ensuring blood safety, developing technologies like the INTERCEPT Blood System, which is approved for pathogen reduction in platelets and plasma. The company aims to lead in global blood products.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 4:40 p.m. ET.

A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005212/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When is the Cerus Corporation participation in the Stifel Virtual Healthcare Conference?

Cerus Corporation will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 4:40 p.m. ET.

Who from Cerus Corporation will speak at the Stifel Conference?

William ‘Obi’ Greenman, CEO, and Kevin D. Green, CFO, will represent Cerus Corporation at the conference.

Where can I watch the Cerus Corporation conference presentation?

You can watch the live webcast of Cerus Corporation's presentation on their Investor Relations page.

What is Cerus Corporation known for?

Cerus Corporation is focused on safeguarding the world’s blood supply with technologies like the INTERCEPT Blood System.

What regulatory status does the INTERCEPT Blood System have?

The INTERCEPT Blood System for platelets and plasma is CE Mark and FDA approved, while the red blood cell system is under regulatory review in Europe.